Carol Werther joins HCW as senior biotech analyst

Carol Ann Werther has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.

Ms. Werther joins HCW with over 20 years of experience in the biotechnology sector both as a research analyst and portfolio manager, including stints with CRT Capital Group, Summer Street Research Partners, Think Equity Partners, Adams, Harkness & Hill and Cowen.

“We are excited to have Carol join HCW’s biotech research team as our seventh senior analyst,” CEO, Mark Viklund, said in a statement.  “Her depth of knowledge in the biotechnology sector acquired over her distinguished career will enable HCW to provide differentiated investment advice to our clients.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.